910044-07-4 Usage
Description
6-bromo-pyridine-2-carboxylic acid tert-butyl ester is a pyridine derivative with a molecular formula of C11H13BrN2O2. It features a tert-butyl ester group attached to the carboxylic acid functional group on the 2-position and a bromine atom on the 6-position. This colorless to light yellow liquid with a characteristic odor is slightly soluble in water but highly soluble in organic solvents. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.
Uses
Used in Pharmaceutical Industry:
6-bromo-pyridine-2-carboxylic acid tert-butyl ester is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-bromo-pyridine-2-carboxylic acid tert-butyl ester serves as an essential building block for the creation of novel agrochemicals, contributing to the advancement of crop protection and management solutions.
Used in Organic Synthesis:
6-bromo-pyridine-2-carboxylic acid tert-butyl ester is utilized as a versatile building block in organic synthesis for the production of a wide range of chemical compounds, showcasing its importance in the field of chemistry and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 910044-07-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,0,0,4 and 4 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 910044-07:
(8*9)+(7*1)+(6*0)+(5*0)+(4*4)+(3*4)+(2*0)+(1*7)=114
114 % 10 = 4
So 910044-07-4 is a valid CAS Registry Number.
910044-07-4Relevant articles and documents
INHIBITORS OF HUMAN ATGL
-
Page/Page column 68; 70; 93-94, (2021/02/05)
The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.
BENZOTHIAZOLE COMPOUNDS
-
Page/Page column 96, (2009/05/29)
The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.
